Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LMBA02 protocol for patients with a Burkitt lymphoma

Trial Profile

LMBA02 protocol for patients with a Burkitt lymphoma

Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Methotrexate; Prednisolone; Vincristine
  • Indications Burkitt's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2016 Results published in The Lancet.
    • 10 Dec 2012 Primary endpoint 'Event-free-survival-rate' has been met.
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top